• Publications
  • Influence
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
BACKGROUND High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present afterExpand
  • 850
  • 55
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
PURPOSE The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. We combined the International Staging System (ISS) withExpand
  • 796
  • 50
  • PDF
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
BACKGROUND Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone hasExpand
  • 629
  • 46
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
BACKGROUND Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone inExpand
  • 850
  • 42
  • PDF
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Treatment of multiple myeloma has substantially changed over the past decade with the introduction of several classes of new effective drugs that have greatly improved the rates and depth ofExpand
  • 851
  • 41
  • PDF
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
Acquired genomic aberrations have been shown to significantly impact survival in several hematologic malignancies. We analyzed the prognostic value of the most frequent chromosomal changes in a largeExpand
  • 783
  • 38
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
BACKGROUND Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma. METHODS In thisExpand
  • 769
  • 33
  • PDF
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
BACKGROUND The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging dataExpand
  • 531
  • 33
  • PDF
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
BACKGROUND Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in thisExpand
  • 480
  • 32
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
We undertook this study to develop uniformly accepted criteria for the definition of organ involvement and response for patients on treatment protocols for immunoglobulin light‐chain amyloidosisExpand
  • 990
  • 31
  • PDF
...
1
2
3
4
5
...